NCT07649681 Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
| NCT ID | NCT07649681 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wuerzburg University Hospital |
| Condition | Multiple Myeloma (MM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 198 participants |
| Start Date | 2026-07-24 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 198 participants in total. It began in 2026-07-24 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation. Although many non-pharmacological recommendations exist, it is unclear which methods are suitable for which individuals. This randomized study aims to compare the effectiveness of individualized dietary recommendations (Gustabor group) with the current standard of care -general recommendations (Control group). Participants will undergo an objective assessment of taste disorders using taste strips and questionnaires. Based on the results, the Gustabor group will receive both general and specific dietary suggestions. These will be accomapnied by AI-generated recipe suggestions tailored to specific taste disorders (e.g., more cold foods in cases of metallic taste). The control group will receive the current standard: a flyer containing general dietary advice for oncology patients previously shown to be beneficial for managing taste alterations. The primary endpoint is the PG-SGA score within 12 weeks of inclusion.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Suffering from one of the following tumor entities: Multiple myeloma, melanoma, urogenital cancer or malignant tumor of the gastrointestinal tract * Mainly oral nutrition * Subjectively perceived tumor therapy-related taste disorder * At least two clinical presentations planned within 12 weeks with a minimum interval of three weeks * Ability to participate in nutritional intervention, including use of the online portal and implementation of recipe suggestions (e.g. resources and access to a kitchen), either independently or with third-party support (e.g. by relatives, outpatient care services). Exclusion Criteria: * Pregnancy * Taste disorder explained by other causes (e.g. existing before therapy or COVID disease) * Placement in an inpatient care facility
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07649681 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma (MM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07649681 currently recruiting?
Yes, NCT07649681 is actively recruiting participants. Contact the research team at Hann_A@ukw.de for enrollment information.
Where is the NCT07649681 trial being conducted?
This trial is being conducted at Augsburg, Germany, Erlangen, Germany, München, Germany, München, Germany and 2 additional locations.
Who is sponsoring the NCT07649681 clinical trial?
NCT07649681 is sponsored by Wuerzburg University Hospital. The trial plans to enroll 198 participants.